Technical Description
The present invention provides N-(1- benzylpiperidin-4-yl)-5-(4-(trifluoromethyl) phenyl)-1,3,4-oxadiazol-2-amine as a multitargeted ligand to treat neurodegenerative disease.
Problems Addressed
- Aβ Accumulation in Brain
- Limitations of Existing Treatments
- Monofunctional Molecules
Tech Features
- Novel Compound
- Multitargeted Ligand
- Inhibits Cholinesterases & BACE-1
- No Toxic Reactions
- Enhanced BBB Permeability
- Low IC50 Value
- Anti-Aβ Aggregation Activity
Target Audience
- Healthcare & Medical Sector
- Pharmaceutical Industry
- Biotechnology Firms
- Research and Development
Tech ID: P27-1241 TRL 5 Patent Status: Granted Available For Exclusive and Non-exclusive License
